112 related articles for article (PubMed ID: 16158966)
1. C-kit expression in dedifferentiated and well-differentiated liposarcomas; immunohistochemistry and genetic analysis.
Tayal S; Classen E; Bemis L; Robinson WA
Anticancer Res; 2005; 25(3B):2215-20. PubMed ID: 16158966
[TBL] [Abstract][Full Text] [Related]
2. Retroperitoneal liposarcomas: follow-up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas.
Fabre-Guillevin E; Coindre JM; Somerhausen Nde S; Bonichon F; Stoeckle E; Bui NB
Cancer; 2006 Jun; 106(12):2725-33. PubMed ID: 16688768
[TBL] [Abstract][Full Text] [Related]
3. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate.
Swick BL; Ravdel L; Fitzpatrick JE; Robinson WA
J Cutan Pathol; 2007 Apr; 34(4):324-9. PubMed ID: 17381803
[TBL] [Abstract][Full Text] [Related]
4. KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.
Loughrey MB; Trivett M; Beshay V; Dobrovic A; Kovalenko S; Murray W; Lade S; Turner H; McArthur GA; Zalcberg J; Waring PM
Histopathology; 2006 Jul; 49(1):52-65. PubMed ID: 16842246
[TBL] [Abstract][Full Text] [Related]
5. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor.
Zheng S; Chen LR; Wang HJ; Chen SZ
Hepatogastroenterology; 2007 Dec; 54(80):2285-90. PubMed ID: 18265649
[TBL] [Abstract][Full Text] [Related]
6. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance.
Boldrini L; Ursino S; Gisfredi S; Faviana P; Donati V; Camacci T; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4101-8. PubMed ID: 15217946
[TBL] [Abstract][Full Text] [Related]
7. Comparative validation of c-kit exon 11 mutation analysis on cytology samples and corresponding surgical resections of gastrointestinal stromal tumours.
Pang NK; Chin SY; Nga ME; Chang AR; Ismail TM; Omar SS; Charlton A; Salto-Tellez M
Cytopathology; 2009 Oct; 20(5):297-303. PubMed ID: 19207305
[TBL] [Abstract][Full Text] [Related]
8. Genetic and pathologic characteristics of gastrointestinal stromal tumors in extragastric lesions.
Cho S; Kitadai Y; Yoshida S; Tanaka S; Yoshihara M; Yoshida K; Chayama K
Int J Mol Med; 2006 Dec; 18(6):1067-71. PubMed ID: 17089009
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of well-differentiated/de-differentiated liposarcomas by high-resolution oligonucleotide array-based comparative genomic hybridization.
Tap WD; Eilber FC; Ginther C; Dry SM; Reese N; Barzan-Smith K; Chen HW; Wu H; Eilber FR; Slamon DJ; Anderson L
Genes Chromosomes Cancer; 2011 Feb; 50(2):95-112. PubMed ID: 21117066
[TBL] [Abstract][Full Text] [Related]
10. Absence of gene mutations in KIT-positive thymic epithelial tumors.
Tsuchida M; Umezu H; Hashimoto T; Shinohara H; Koike T; Hosaka Y; Eimoto T; Hayashi JI
Lung Cancer; 2008 Dec; 62(3):321-5. PubMed ID: 18486988
[TBL] [Abstract][Full Text] [Related]
11. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization.
Nishio J; Iwasaki H; Ishiguro M; Ohjimi Y; Fujita C; Ikegami H; Ariyoshi A; Naito M; Kaneko Y; Kikuchi M
Int J Oncol; 2003 Mar; 22(3):535-42. PubMed ID: 12579306
[TBL] [Abstract][Full Text] [Related]
12. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Wardelmann E; Merkelbach-Bruse S; Pauls K; Thomas N; Schildhaus HU; Heinicke T; Speidel N; Pietsch T; Buettner R; Pink D; Reichardt P; Hohenberger P
Clin Cancer Res; 2006 Mar; 12(6):1743-9. PubMed ID: 16551858
[TBL] [Abstract][Full Text] [Related]
13. Expression and mutation analysis of the tyrosine kinase c-kit in poorly differentiated and anaplastic thyroid carcinoma.
Broecker-Preuss M; Sheu SY; Worm K; Feldkamp J; Witte J; Scherbaum WA; Mann K; Schmid KW; Schott M
Horm Metab Res; 2008 Oct; 40(10):685-91. PubMed ID: 18622894
[TBL] [Abstract][Full Text] [Related]
14. Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy.
Keun Park C; Lee EJ; Kim M; Lim HY; Choi DI; Noh JH; Sohn TS; Kim S; Kim MJ; Lee HK; Kim KM
Ann Surg; 2008 Jun; 247(6):1011-8. PubMed ID: 18520229
[TBL] [Abstract][Full Text] [Related]
15. C-kit expression and mutational analysis in medulloblastoma.
Chilton-Macneill S; Ho M; Hawkins C; Gassas A; Zielenska M; Baruchel S
Pediatr Dev Pathol; 2004; 7(5):493-8. PubMed ID: 15547773
[TBL] [Abstract][Full Text] [Related]
16. Significance of loss of heterozygosity of the RB1 gene during tumour progression in well-differentiated liposarcomas.
Schneider-Stock R; Boltze C; Jaeger V; Stumm M; Seiler C; Rys J; Schütze K; Roessner A
J Pathol; 2002 Aug; 197(5):654-60. PubMed ID: 12210086
[TBL] [Abstract][Full Text] [Related]
17. c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment.
Raspollini MR; Amunni G; Villanucci A; Pinzani P; Simi L; Paglierani M; Taddei GL
Clin Cancer Res; 2004 May; 10(10):3500-3. PubMed ID: 15161707
[TBL] [Abstract][Full Text] [Related]
18. An immunohistochemical and molecular study of gastrointestinal stromal tumours.
Teong YT; Teo ST; Tan LP; Wu BQ; Peh SC
Med J Malaysia; 2006 Dec; 61(5):526-33. PubMed ID: 17623951
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.
Lee HE; Kim MA; Lee HS; Lee BL; Kim WH
J Clin Pathol; 2008 Jun; 61(6):722-9. PubMed ID: 18381383
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical and mutational analysis of c-kit in gastrointestinal neuroendocrine cell carcinoma.
Ishikubo T; Akagi K; Kurosumi M; Yamaguchi K; Fujimoto T; Sakamoto H; Tanaka Y; Ochiai A
Jpn J Clin Oncol; 2006 Aug; 36(8):494-8. PubMed ID: 16844734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
